Monday, June 23, 1997
Staying the course of opposition
Redux dexfenfluramine for obesity has been marketed in the U.S. for a year, but that hasn't stopped its opponents from continuing their campaign against the drug through the general media.
The detractors appear to represent a small but vocal and highly active group that includes Mark Molliver, a professor of neuroscience and neurology at Johns Hopkins University, and Lewis Seiden, a professor of pharmacology at the University of Chicago. They allege that Redux causes neurotoxicity and poses the risk of developing PPH (primary pulmonary hypertension), a fatal lung disorder associated both with anorectic drugs and obesity.